

## Author Index for Volume 18

- Aalto P, 140  
 Adams HP Jr, 358  
 Adams J, 14  
 Azen SP, 168
- Babiker AG, 1, 460  
 Barton FB, 420  
 Baum M, 1  
 Bendixen BH, 358  
 Blackstone EH, 488  
 Block JE, 54  
 Bonadonna G, 1  
 Bonds DR, 420  
 Bouckaert A, 58  
 Boyd NF, 241  
 Brody BA, 602  
 Brown MB, 445  
 Buchwald H, 478  
 Burkham-Kreitner S, 383  
 Buyse M, 1
- Califf RM, 651  
 Campeau L, 318  
 Canadian Lung Oncology Group, 27  
 Canner PL, 318  
 Cannon C, 517  
 Cappelleri JC, 431  
 Chamberlain RM, 228  
 Clarke M, 1  
 Clarke WR, 358  
 Colby C, 251  
 Collins R, 1  
 COMMIT Research Group, 131  
 Cook DJ, 27, 121  
 Corle DK, 131  
 Crott R, 58
- Dalesio O, 1  
 Darbyshire JH, 1, 460  
 Davies C, 1  
 Davis CE, 557  
 Davis PH, 358  
 DeMets DL, 637  
 Dixon DO, 87  
 Doll R, 1  
 Donaldson C, 464  
 Donta S, 397
- Drescher C, 251  
 Dunn M, 168
- Elbourne D, 1  
 Ellenberg SS, 628  
 Etzioni R, 251
- Farkouh ME, 568  
 Feldman HA, 380  
 Flather MD, 568  
 Fleishman S, 286  
 Frankowski RF, 228  
 Freedman LS, 131  
 Frick MH, 93
- Gail MH, 131  
 Geller NL, 222, 318, 420  
 Gent M, 546  
 Geraci E, 621  
 Glasziou PP, 464  
 Goetzghebeur E, 187  
 Goldhirsch A, 1  
 Gray R, 1  
 Green MR, 286  
 Green SB, 131, 306, 506  
 Greenberg C, 241  
 Grimsman KJ, 358  
 Guyatt GH, 27
- Haber H, 93  
 Hakama M, 140  
 Hall J, 464  
 Hemminki E, 140  
 Herndon JE II, 286  
 Hertert S, 328  
 Hill C, 1  
 Hill K, 328  
 Hodis HN, 168  
 Hofstetter CR, 383  
 Hokkanen T, 140  
 Hovell MF, 383  
 Huhtala H, 140  
 Hunninghake DB, 328
- Insull W, 84  
 Ioannidis JPA, 431  
 Iwane M, 65, 397
- Jones JA, 383
- Jylhä M, 140
- Kalish LA, 380  
 Karjalainen S, 140  
 Karnash SL, 651  
 Karrison TG, 151  
 Keating K, 383  
 Kesäniemi YA, 93  
 King D, 27  
 Kirklin JW, 488  
 Knatterud GL, 318, 514  
 Korn EL, 275  
 Kosty MP, 286  
 Kristal AR, 241  
 Kriukov V, 241
- Lachenbruch PA, 381  
 Lau J, 431  
 Leon AC, 378  
 Liang W-M, 445  
 Lipid Study Group, 464  
 Lockwood GA, 241  
 Lovato LC, 328  
 Love BB, 358
- Machin D, 301  
 Mack WJ, 168  
 Manninen V, 93  
 Martin LJ, 241  
 McMahon RP, 420  
 Moynour CM, 311  
 Morrison TC, 383  
 Musa D, 14
- Naftel DC, 488  
 Nawrocki JW, 93  
 Ng J, 204  
 Nieminen MS, 93
- O'Brien BJ, 121  
 O'Brien PC, 222  
 O'Neill RT, 550
- Palensky J, 65  
 Parmar M, 1  
 Pasternack A, 93  
 Peduzzi P, 397  
 Peele P, 14  
 Pelusio RM, 461

- Peto R, 1  
 Peto TEA, 460  
 Plante K, 65  
 Pocock SJ, 530  
 Pogue J, 568, 580  
 Prentice RL, 561  
 Probstfield JL, 328  
  
 Quan H, 204  
  
 Rosenkranz G, 43  
 Russos S, 383  
 Rutqvist L, 1  
  
 Sackett D, 1  
 Sacks HS, 431  
 Scott CB, 277  
 Second Joint Meeting of  
     the Society for  
     Clinical Trials and  
     the International  
     Society of Clinical  
     Biostatistics (Ab-  
     stracts), 18(3S):41S  
 Shatuck AL, 241  
 Silverman M, 14  
 Simes RJ, 464  
 Slymen DJ, 383  
 Stampfer M, 494  
 Stepanavage ME, 204  
 Stewart H, 1  
 Suchanek Hudmon K, 228  
 Syväne M, 93  
  
 Taskinen M-R, 93  
 Temple RJ, 613  
 Terrin ML, 420, 500  
 Thompson B, 318  
 Tognoni G, 621  
 Troyan S, 27  
 Tuimala R, 140  
 Turner ME, 488  
  
 Urban N, 251  
  
 Valagussa P, 1  
 Vrijens B, 187  
  
 Waclawiw MA, 420  
 Wahlgren DR, 383  
 Waller LA, 180  
 Walter SD, 27  
 Wasek PA, 358  
 Wichman A, 271  
 Willan AR, 121  
 Williams GW, 661  
 Woodlief LH, 651  
 Woolson RF, 358  
  
 Yusuf S, 568, 580, 594  
  
 Zakarian J, 383  
 Zhang J, 204  
 Zucker D, 318

## Subject Index for Volume 18

### ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

AIDS Clinical Trials (book review), 460

### ACTIVE CONTROL

When Are Clinical Trials of a Given Agent vs. Placebo No Longer Appropriate or Feasible?, 613

### ACUTE TREATMENT

Clinical Perspectives on the Use of Composite Endpoints, 517  
Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358

### ADHERENCE

Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

### ADJUDICATORS

Outcome Assessment for Clinical Trials: How Many Adjudicators Do We Need?, 27

### ADOLESCENTS

Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attention Bias, 383

### AGED

Recruiting Older Adults for Clinical Trials, 14

### $\alpha$ -LEVEL

Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204

### ALTERNATE ASSIGNMENT

A Note on Harold S. Diehl, Randomization, and Clinical Trials, 180

### ANALYSIS

Errors, Misunderstandings, and Fraud, 661

Outcome Assessment for Clinical Trials: How Many Adjudicators Do We Need?, 27

### ANGIOGRAPHIC ENDPOINTS

A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168

### ANTITHROMBOTIC THERAPY

Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358

### APPROVAL

*Ethical Issues in Drug Testing, Approval, and Pricing: The Clot-Dissolving Drugs* (book review), 271

### ASSESSMENT

Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference?, 275, 301, 306  
Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference? A Discussion, 275, 301, 306

Assessment of a Food Frequency

Questionnaire as a Screening Tool for Low Fat Intakes, 241

Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy, 121

Outcome Assessment for Clinical Trials: How Many Adjudicators Do We Need?, 27

### ATHEROSCLEROSIS

A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibrin-Acid Derivative in Men after Coronary Bypass Surgery, 93

**ATTRITION BIAS**

- Tracking and Follow-Up of 16,915  
Adolescents: Minimizing  
Attrition Bias, 383

**AUDITING**

- Errors, Misunderstandings, and Fraud,  
661

**BAYESIAN METHODS**

- Bayesian Methods and Ethics in a Clinical  
Trial Design* (book review), 87

**BEHAVIORAL MODIFICATION**

- Individual Subject Random Assignment  
Is the Preferred Means of  
Evaluating Behavioral Lifestyle  
Modification, 500
- Observational Epidemiology is the  
Preferred Means of Evaluating  
Effects of Behavioral and Lifestyle  
Modification, 494

**BENEFIT-RISK RATIO**

- Benefit-Risk Ratios in the Assessment of  
the Clinical Evidence of a New  
Therapy, 121

**BIAS**

- Distinctions between Fraud, Bias, Errors,  
Misunderstanding, and  
Incompetence, 637
- The Relationship between Study Design,  
Results, and Reporting of  
Randomized Clinical Trials of HIV  
Infection, 431
- Tracking and Follow-Up of 16,915  
Adolescents: Minimizing  
Attrition Bias, 383

**BIBLIOGRAPHY**

- Recruitment for Controlled Clinical  
Trials: Literature Summary and  
Annotated Bibliography, 328

**BINARY LONGITUDINAL DATA**

- Comparing Compliance Patterns  
Between Randomized  
Treatments, 187

**BIOMEDICAL STUDIES**

- A User's Review of Commercial Sample  
Size Software for Design of  
Biomedical Studies Using Survival  
Data, 65

**BYPASS**

- An Application of the Zucker-Wittes  
Modified Ratio Estimate in the  
Post Coronary Artery Bypass  
Graft (CABG) Clinical Trial, 318
- A Study to Determine the Response of  
Coronary Atherosclerosis to  
Raising Low High Density  
Lipoprotein Cholesterol with a  
Fibric-Acid Derivative in Men  
after Coronary Bypass Surgery,  
93

**CANCER**

- Assessing Quality of Life in Comparative  
Cancer Clinical Trials: Does It  
Make A Difference?, 275, 301, 306
- Assessing Quality of Life in Comparative  
Cancer Clinical Trials: Does It  
Make A Difference? A Discussion,  
275, 301, 306
- Do Quality of Life Assessments Make a  
Difference in the Evaluation of  
Cancer Treatments?, 311
- A Longitudinal Study of Quality of Life  
in Advanced Non-Small Cell  
Lung Cancer: Cancer and  
Leukemia Group B (CALGB)  
8931, 286
- Outcomes of a Placebo Run-In Period in  
a Head and Neck Cancer  
Chemoprevention Trial, 228
- Quality-Adjusted Survival Analysis of  
Malignant Glioma Patients, 277
- Use of a Stochastic Simulation Model to  
Identify an Efficient Protocol for  
Ovarian Cancer Screening, 251

**CENSORING**

- Use of Irwin's Restricted Mean as an  
Index for Comparing Survival in  
Different Treatment  
Groups—Interpretation and  
Power Considerations, 151

**CHEMOPREVENTION TRIALS**

- Outcomes of a Placebo Run-In Period in  
a Head and Neck Cancer  
Chemoprevention Trial, 228

**CHOLESTEROL**

- A Study to Determine the Response of  
Coronary Atherosclerosis to  
Raising Low High Density  
Lipoprotein Cholesterol with a  
Fibric-Acid Derivative in Men after  
Coronary Bypass Surgery, 93

**CLINICAL EVIDENCE**

Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy, 121

**CLINICAL PREDICTIONS**

Influence of Study Goals on Study Design and Execution, 488

**CLINICAL RESEARCH**

Clinical Research in Pharmaceutical Development (book review), 461

**CLINICAL TRIALS**

AIDS Clinical Trials (book review), 460

An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318

Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference?, 275, 301, 306

Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference? A Discussion, 275, 301, 306

*Bayesian Methods and Ethics in a Clinical Trial Design* (book review), 87

Clinical Perspectives on the Use of Composite Endpoints, 517

Clinical Trials with Multiple Outcomes: A Statistical Perspective on their Design, Analysis, and Interpretation, 530

Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464

Developing Systems for Cost-Effective Auditing of Clinical Trials, 651

Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments?, 311

An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), 420

Interpreting Tests for Efficacy in Clinical Trials With Multiple Endpoints, 222

A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

A Note on Harold S. Diehl, Randomization, and Clinical Trials, 180

On the Role and Analysis of Secondary Outcomes in Clinical Trials, 561

Outcome Assessment for Clinical Trials: How Many Adjudicators Do We Need?, 27

Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

Patient Managed Clinical Trial, 141

*Patient Recruitment in Clinical Trials* (book review), 84

Recruiting Older Adults for Clinical Trials, 14

Recruitment for Controlled Clinical Trials: Literature Summary and Annotated Bibliography, 328

Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204

A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibrin-Acid Derivative in Men after Coronary Bypass Surgery, 93

Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251

Why Clinical Trials in the Evaluation of Life Style Evaluation?, 514

**CLOT-DISSOLVING DRUGS**

*Ethical Issues in Drug Testing, Approval, and Pricing: The Clot-Dissolving Drugs* (book review), 271

**CLUSTERS**

Some Issues in the Construction and Use of Clusters of Outcome Events, 546

**COHORT MAINTENANCE**

Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383

**COMMERCIAL SAMPLE SIZE SOFTWARE**

A User's Review of Commercial Sample Size Software for Design of Biomedical Studies Using Survival Data, 65

# **COMMUNITY INTERVENTION TRIAL FOR SMOKING CESSATION (COMMIT)**

The Efficiency of the Matched-Pairs Design of the Community Intervention Trial for Smoking Cessation (COMMIT), 131

# **COMMUNITY STUDIES**

The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification, 506

Individual Subject Random Assignment Is the Preferred Means of Evaluating Behavioral Lifestyle Modification, 500

# **COMPARISON**

Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference?, 275, 301, 306

Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference? A Discussion, 275, 301, 306

Comparing Compliance Patterns Between Randomized Treatments, 187

A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168

# **COMPLIANCE PATTERNS**

Comparing Compliance Patterns Between Randomized Treatments, 187

Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

# **COMPOSITE ENDPOINTS**

Clinical Perspectives on the Use of Composite Endpoints, 517

Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204

# **COMPUTERIZED ENDPOINT MEASURES**

A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168

# **CONDITIONAL POWER**

An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), 420

# **CONTROL GROUP SELECTION**

A Note on Harold S. Diehl, Randomization, and Clinical Trials, 180

# **CORONARY ATHEROSCLEROSIS**

A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibrin-Acid Derivative in Men after Coronary Bypass Surgery, 93

# **CORONARY BYPASS SURGERY**

A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibrin-Acid Derivative in Men after Coronary Bypass Surgery, 93

# **CORONARY ENDPOINT MEASURES**

A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168

# **COST EFFECTIVENESS**

Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464

Developing Systems for Cost-Effective Auditing of Clinical Trials, 651

Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383

Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251

# **COVARIATES**

Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

**DATA COLLECTION**

Developing Systems for Cost-Effective  
Auditing of Clinical Trials, 651

**DEFERRED CONSENT**

Informed Consent: Protection or  
Obstacle? Some Emerging  
Issues, 628

**DEVICE RANDOMIZED CLINICAL  
TRIALS**

Surgical Procedures and Devices Should  
Be Evaluated in the Same Way as  
Medical Therapy, 478

**DIEHL, HAROLD S.**

A Note on Harold S. Diehl,  
Randomization, and Clinical  
Trials, 180

**DIETARY ASSESSMENT**

Assessment of a Food Frequency  
Questionnaire as a Screening  
Tool for Low Fat Intakes, 241

**DIFFERENCE**

The Difference in Mean Costs as a  
Pharmacoeconomic Outcome  
Variable: Power Considerations, 58

**DOCTOR-PATIENT RELATIONSHIP**

Approaches to Informed Consent, 621

**DOSE FINDING**

Can We Reduce the Dose of a Vaccine?, 43

**DOUBLE BLIND**

The Relationship between Study Design,  
Results, and Reporting of  
Randomized Clinical Trials of HIV  
Infection, 431

**DRUG TESTING**

*Ethical Issues in Drug Testing, Approval,  
and Pricing: The Clot-Dissolving  
Drugs* (book review), 271

**EFFICACY**

The Efficiency of the Matched-Pairs  
Design of the Community  
Intervention Trial for Smoking  
Cessation (COMMIT), 131  
Interpreting Tests for Efficacy in  
Clinical Trials With Multiple  
Endpoints, 222

**EMERGENCY TREATMENT**

Informed Consent: Protection or  
Obstacle? Some Emerging  
Issues, 628

**ENDPOINTS**

A Comparison of Quantitative  
Computerized and Human Panel  
Coronary Endpoint Measures:  
Implications for the Design of  
Angiographic Trials, 168  
Interpreting Tests for Efficacy in  
Clinical Trials With Multiple  
Endpoints, 222  
Some Statistical Methods for Multiple  
Endpoints in Clinical Trials, 204

**EPIDEMIOLOGY**

Observational Epidemiology is the  
Preferred Means of Evaluating  
Effects of Behavioral and Lifestyle  
Modification, 494

**EQUIPOISE**

When Are Placebo-Controlled Trials No  
Longer Appropriate?, 602

**EQUIVALENCE STUDY**

Can We Reduce the Dose of a Vaccine?, 43

**ERROR**

Distinctions between Fraud, Bias, Errors,  
Misunderstanding, and  
Incompetence, 637  
Do Quality of Life Assessments Make a  
Difference in the Evaluation of  
Cancer Treatments?, 311  
Errors, Misunderstandings, and Fraud,  
661  
Some Statistical Methods for Multiple  
Endpoints in Clinical Trials, 204

**ETHICS**

Approaches to Informed Consent, 621  
*Bayesian Methods and Ethics in a Clinical  
Trial Design* (book review), 87  
*Ethical Issues in Drug Testing, Approval,  
and Pricing: The Clot-Dissolving  
Drugs* (book review), 271  
Informed Consent: Protection or Obstacle?  
Some Emerging Issues, 628  
When Are Placebo-Controlled Trials No  
Longer Appropriate?, 602

**EVALUATION**

The Advantages of Community-  
Randomized Trials for



- Evaluating Lifestyle Modification, 506
- Surgical Procedures and Devices Should Be Evaluated in the Same Way as Medical Therapy, 478
- Why Clinical Trials in the Evaluation of Life Style Evaluation?, 514

#### **EXERCISE**

- Interpreting Studies of Exercise and Osteoporosis: A Call for Rigor, 54

#### **FAT INTAKE**

- Assessment of a Food Frequency Questionnaire as a Screening Tool for Low Fat Intakes, 241

#### **FIBRIC-ACID DERIVATIVE**

- A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93

#### **FISHER, BERNARD, MD**

- The Trials of Dr. Bernard Fisher: A European Perspective of an American Episode, 1

#### **FOLLOW-UP**

- Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383

#### **FOOD AND DRUG**

##### **ADMINISTRATION (FDA)**

- Informed Consent: Protection or Obstacle? Some Emerging Issues, 628
- Surgical Procedures and Devices Should Be Evaluated in the Same Way as Medical Therapy, 478

#### **FOOD FREQUENCY**

##### **QUESTIONNAIRE**

- Assessment of a Food Frequency Questionnaire as a Screening Tool for Low Fat Intakes, 241

#### **FRAUD**

- Distinctions between Fraud, Bias, Errors, Misunderstanding, and Incompetence, 637
- Errors, Misunderstandings, and Fraud, 661

#### **GENERALIZED ESTIMATING QUESTIONS**

- Comparing Compliance Patterns Between Randomized Treatments, 187

#### **GERIATRIC ASSESSMENT**

- Recruiting Older Adults for Clinical Trials, 14

#### **GLIOMA**

- Quality-Adjusted Survival Analysis of Malignant Glioma Patients, 277

#### **GRAFT**

- An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318

#### **HALF-SAMPLE ESTIMATION**

- A Median-Based Test Under Informative Dropout: The One-Sample Case, 445

#### **HEAD AND NECK CANCER**

- Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

#### **HEPARINOID**

- Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358

#### **HHS REGULATIONS**

- Informed Consent: Protection or Obstacle? Some Emerging Issues, 628

#### **HIGH DENSITY LIPOPROTEIN CHOLESTEROL**

- A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93

#### **HISTORY OF CLINICAL TRIALS**

- A Note on Harold S. Diehl, Randomization, and Clinical Trials, 180



**HUMAN IMMUNODEFICIENCY  
VIRUS (HIV) INFECTION**

The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431

A Review of the Design of Vaccine Efficacy Trials and a Proposal for the Design of the VA Cooperative Study of Active Immunotherapy of HIV Infection, 397

**HUMAN PANEL ENDPOINT  
MEASURES**

A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168

**HUMAN STUDIES**

Observational Epidemiology is the Preferred Means of Evaluating Effects of Behavioral and Lifestyle Modification, 494

**HYDRAZINE SULFATE**

A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

**HYPOTHESIS TESTS**

Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance, 550, 557

**INCOMPETENCE**

Distinctions between Fraud, Bias, Errors, Misunderstanding, and Incompetence, 637

**INDEX**

Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

**INDIVIDUAL SUBJECT RANDOM  
ASSIGNMENT**

Individual Subject Random Assignment Is the Preferred Means of Evaluating Behavioral Lifestyle Modification, 500

**INFORMATIVE DROPOUT**

A Median-Based Test Under Informative Dropout: The One-Sample Case, 445

**INFORMED CONSENT**

Approaches to Informed Consent, 621  
Informed Consent: Protection or Obstacle? Some Emerging Issues, 628  
When Are Placebo-Controlled Trials No Longer Appropriate?, 602

**INTENT-TO-TREAT**

A Review of the Design of Vaccine Efficacy Trials and a Proposal for the Design of the VA Cooperative Study of Active Immunotherapy of HIV Infection, 397

**INTERIM MONITORING**

An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), 420

**INTERPRETATION**

Interpreting Studies of Exercise and Osteoporosis: A Call for Rigor, 54  
Interpreting Tests for Efficacy in Clinical Trials With Multiple Endpoints, 222  
Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

**INTERVENTION STUDIES**

The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification, 506

**IRWIN'S RESTRICTED MEAN**

Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

**ISCHEMIC HEART DISEASE**

Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464

**ISCHEMIC STROKE**

Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358

**LEUKEMIA**

A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

**LIFESTYLE MODIFICATION**

The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification, 506

Individual Subject Random Assignment Is the Preferred Means of Evaluating Behavioral Lifestyle Modification, 500

Observational Epidemiology is the Preferred Means of Evaluating Effects of Behavioral and Lifestyle Modification, 494

Why Clinical Trials in the Evaluation of Life Style Evaluation?, 514

**LIPID TRIAL**

Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464

**LIPOPROTEINS**

A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibrin-Acid Derivative in Men after Coronary Bypass Surgery, 93

**LITERATURE SUMMARY**

Recruitment for Controlled Clinical Trials: Literature Summary and Annotated Bibliography, 328

**LONGITUDINAL STUDY**

A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

**LUNG CANCER**

A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

**MAGNESIUM**

Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580

**MANAGEMENT**

Patient Managed Clinical Trial, 141

**MATCHED PAIRS DESIGN**

The Efficiency of the Matched-Pairs Design of the Community Intervention Trial for Smoking Cessation (COMMIT), 131

**MEASUREMENT ERROR**

Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments?, 311

**MEDIAN TEST**

A Median-Based Test Under Informative Dropout: The One-Sample Case, 445

**MEDICAL THERAPY**

Surgical Procedures and Devices Should Be Evaluated in the Same Way as Medical Therapy, 478

**MEDICATION EVENT**

**MONITORING SYSTEMS**  
Comparing Compliance Patterns Between Randomized Treatments, 187

**META-ANALYSIS**

Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580

Meta-Analysis of Randomized Trials: Looking Back and Looking Ahead, 594

The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431

Strengths and Limitations of Meta-Analysis: Larger Studies May Be More Reliable, 568

**MISSING DATA**

Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments?, 311

**MISUNDERSTANDING**

- Distinctions between Fraud, Bias, Errors, Misunderstanding, and Incompetence, 637  
Errors, Misunderstandings, and Fraud, 661

**MONITORING**

- Developing Systems for Cost-Effective Auditing of Clinical Trials, 651

**MULTIPLE ENDPOINTS**

- Interpreting Tests for Efficacy in Clinical Trials With Multiple Endpoints, 222  
Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204

**MULTIPLE OUTCOME EVENTS**

- Clinical Trials with Multiple Outcomes: A Statistical Perspective on their Design, Analysis, and Interpretation, 530  
On the Role and Analysis of Secondary Outcomes in Clinical Trials, 561  
Some Issues in the Construction and Use of Clusters of Outcome Events, 546

**MULTIVARIATE FAILURE TIMES**

- On the Role and Analysis of Secondary Outcomes in Clinical Trials, 561

**MYOCARDIAL INFARCTION**

- Clinical Perspectives on the Use of Composite Endpoints, 517  
Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580

**NEW THERAPY**

- Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy, 121

**NON-SMALL CELL LUNG CANCER**

- A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

**OBSERVATIONAL STUDIES**

- Individual Subject Random Assignment Is the Preferred Means of

Evaluating Behavioral Lifestyle Modification, 500

- Influence of Study Goals on Study Design and Execution, 488

**ODDS RATIO**

- The Odds Ratio (letter), 381

**OLDER ADULTS**

- Recruiting Older Adults for Clinical Trials, 14

**ONE-SAMPLE CASE**

- A Median-Based Test Under Informative Dropout: The One-Sample Case, 445

**OSTEOPOROSIS**

- Interpreting Studies of Exercise and Osteoporosis: A Call for Rigor, 54

**OUTCOME ASSESSMENT**

- Influence of Study Goals on Study Design and Execution, 488  
Outcome Assessment for Clinical Trials: How Many Adjudicators Do We Need?, 27

**OUTCOME VARIABLE**

- The Difference in Mean Costs as a Pharmacoeconomic Outcome Variable: Power Considerations, 58

**OVARIAN CANCER**

- Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251

**OVERVIEW**

- Strengths and Limitations of Meta-Analysis: Larger Studies May Be More Reliable, 568

**PALLIATION**

- Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments?, 311

**PATIENT MANAGEMENT**

- Patient Managed Clinical Trial, 141

**PATIENT RECRUITMENT**

- Patient Recruitment in Clinical Trials* (book review), 84

Recruitment for Controlled Clinical Trials: Literature Summary and Annotated Bibliography, 328

#### **PHARMACEUTICAL DEVELOPMENT**

Clinical Research in Pharmaceutical Development (book review), 461

#### **PHARMACOECONOMIC TRIAL**

The Difference in Mean Costs as a Pharmacoeconomic Outcome Variable: Power Considerations, 58

#### **PHASE III TRIALS**

Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference?, 275, 301

#### **PHONE LINES**

Number of Phone Lines for Telephone Randomization (letter), 380

#### **PLACEBO**

Informed Consent: Protection or Obstacle? Some Emerging Issues, 628

Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

When Are Clinical Trials of a Given Agent vs. Placebo No Longer Appropriate or Feasible?, 613

When Are Placebo-Controlled Trials No Longer Appropriate?, 602

#### **POISSON PROCESS**

An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), 420

#### **POST CORONARY ARTERY BYPASS GRAFT**

An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318

#### **POWER**

The Difference in Mean Costs as a Pharmacoeconomic Outcome Variable: Power Considerations, 58

Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

#### **PREVENTION TRIALS**

Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

#### **PRICING**

*Ethical Issues in Drug Testing, Approval, and Pricing: The Clot-Dissolving Drugs* (book review), 271

#### **PRIMARY ENDPOINTS**

Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance, 550, 557

#### **PUBLICATION BIAS**

The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431

#### **p-VALUES**

Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance, 550, 557

Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204

#### **QUALITY CONTROL**

Errors, Misunderstandings, and Fraud, 661

#### **QUALITY OF LIFE**

Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference?, 275, 301, 306

Assessing Quality of Life in Comparative Cancer Clinical Trials: Does It Make A Difference? A Discussion, 275, 301, 306

Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464

Do Quality of Life Assessments Make a Difference in the Evaluation of Cancer Treatments?, 311

A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer: Cancer and Leukemia Group B (CALGB) 8931, 286

Quality-Adjusted Survival Analysis of  
Malignant Glioma Patients, 277

#### **QUANTITATIVE COMPUTERIZED ENDPOINT MEASURES**

A Comparison of Quantitative  
Computerized and Human  
Panel Coronary Endpoint  
Measures: Implications for the  
Design of Angiographic Trials, 168

#### **QUESTIONNAIRES**

Assessment of a Food Frequency  
Questionnaire as a Screening  
Tool for Low Fat Intakes, 241

#### **RANDOM ALLOCATION**

The Advantages of Community-  
Randomized Trials for Evaluating  
Lifestyle Modification, 506

#### **RANDOMIZED CONSENT DESIGN**

Informed Consent: Protection or Obstacle?  
Some Emerging Issues, 628

#### **RANDOMIZED CONTROLLED CLINICAL TRIALS**

The Advantages of Community-  
Randomized Trials for  
Evaluating Lifestyle  
Modification, 506  
Assessing Quality of Life in Comparative  
Cancer Clinical Trials: Does It  
Make A Difference?, 275, 301, 306  
Assessing Quality of Life in Comparative  
Cancer Clinical Trials: Does It  
Make A Difference? A Discussion,  
275, 301, 306  
Comparing Compliance Patterns  
Between Randomized  
Treatments, 187  
Cumulating Evidence from Randomized  
Trials: Utilizing Sequential  
Monitoring Boundaries for  
Cumulative Meta-Analysis, 580  
Design of a Cost-Effectiveness Study  
within a Randomized Trial: The  
LIPID Trial for Secondary  
Prevention of IHD, 464  
Distinctions between Fraud, Bias, Errors,  
Misunderstanding, and  
Incompetence, 637  
Meta-Analysis of Randomized Trials:  
Looking Back and Looking  
Ahead, 594  
A Note on Harold S. Diehl,  
Randomization, and Clinical  
Trials, 180

Number of Phone Lines for Telephone  
Randomization (letter), 380

Observational Epidemiology is the  
Preferred Means of Evaluating  
Effects of Behavioral and Lifestyle  
Modification, 494

The Relationship between Study Design,  
Results, and Reporting of  
Randomized Clinical Trials of HIV  
Infection, 431

A Review of the Design of Vaccine  
Efficacy Trials and a Proposal for  
the Design of the VA Cooperative  
Study of Active Immunotherapy  
of HIV Infection, 397

Some Issues in the Construction and Use  
of Clusters of Outcome Events,  
546

Strengths and Limitations of Meta-  
Analysis: Larger Studies May Be  
More Reliable, 568

Surgical Procedures and Devices Should  
Be Evaluated in the Same Way  
as Medical Therapy, 478

When Are Clinical Trials of a Given  
Agent vs. Placebo No Longer  
Appropriate or Feasible?, 613

#### **RATIO ESTIMATE**

An Application of the Zucker-Wittes  
Modified Ratio Estimate in the  
Post Coronary Artery Bypass  
Graft (CABG) Clinical Trial, 318  
Benefit-Risk Ratios in the Assessment of  
the Clinical Evidence of a New  
Therapy, 121  
The Odds Ratio (letter), 381

#### **RECRUITMENT**

*Patient Recruitment in Clinical Trials* (book  
review), 84  
Recruiting Older Adults for Clinical  
Trials, 14  
Recruitment for Controlled Clinical  
Trials: Literature Summary and  
Annotated Bibliography, 328

#### **REDUCTION**

Can We Reduce the Dose of a Vaccine?, 43

#### **REPORTING**

The Relationship between Study Design,  
Results, and Reporting of  
Randomized Clinical Trials of HIV  
Infection, 431

**RESTRICTED MEAN**

Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

**RESULTS**

The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431

**RUN-IN**

Outcomes of a Placebo Run-In Period in a Head and Neck Cancer Chemoprevention Trial, 228

**SAMPLING BIAS**

Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383

**SCREENING TOOL**

Assessment of a Food Frequency Questionnaire as a Screening Tool for Low Fat Intakes, 241  
Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251

**SECONDARY ENDPOINTS**

Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance, 550, 557

**SECONDARY OUTCOMES**

On the Role and Analysis of Secondary Outcomes in Clinical Trials, 561

**SECONDARY PREVENTION**

Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464

**SEQUENTIAL MONITORING**

Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580  
On the Role and Analysis of Secondary Outcomes in Clinical Trials, 561

**SIDE EFFECTS**

Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy, 121

**SIMULATION**

The Difference in Mean Costs as a Pharmacoeconomic Outcome Variable: Power Considerations, 58  
An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), 420  
Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251

**SMOKING**

The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification, 506  
The Efficiency of the Matched-Pairs Design of the Community Intervention Trial for Smoking Cessation (COMMIT), 131

**SOFTWARE**

Software Review, 378, 184  
A User's Review of Commercial Sample Size Software for Design of Biomedical Studies Using Survival Data, 65

**STATISTICAL METHODS**

The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification, 506  
Some Statistical Methods for Multiple Endpoints in Clinical Trials, 204  
An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318  
Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance, 550, 557

**STOCHASTIC PROCESSES**

Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580



**STOCHASTIC SIMULATION MODEL**

Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening, 251

**STREPTOKINASE**

Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580

**STROKE**

Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358

**STUDY DESIGN**

*Bayesian Methods and Ethics in a Clinical Trial Design* (book review), 87

A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials, 168

Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD, 464

Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358

The Efficiency of the Matched-Pairs Design of the Community Intervention Trial for Smoking Cessation (COMMIT), 131

Errors, Misunderstandings, and Fraud, 661

Influence of Study Goals on Study Design and Execution, 488

Recruitment for Controlled Clinical Trial: Literature Summary and Annotated Bibliography, 328

The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection, 431

A User's Review of Commercial Sample Size Software for Design of Biomedical Studies Using Survival Data, 65

**STUDY GOALS**

Influence of Study Goals on Study Design and Execution, 488

**SUMMARY STATISTICS**

Comparing Compliance Patterns Between Randomized Treatments, 187

**SURGERY**

An Application of the Zucker-Wittes Modified Ratio Estimate in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial, 318

A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery, 93

Surgical Procedures and Devices Should Be Evaluated in the Same Way as Medical Therapy, 478

**SURVIVAL ANALYSIS**

Assessing Quality of Life in Comparative Cancer Clinical Trial: Does It Make A Difference?, 275, 301

Assessing Quality of Life in Comparative Cancer Clinical Trial: Does It Make A Difference? A Discussion, 275, 301, 306

Quality-Adjusted Survival Analysis of Malignant Glioma Patients, 277

Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations, 151

A User's Review of Commercial Sample Size Software for Design of Biomedical Studies Using Survival Data, 65

**TELEPHONE RANDOMIZATION**

Number of Phone Lines for Telephone Randomization (letter), 380

**THROMBOLYSIS**

Clinical Perspectives on the Use of Composite Endpoints, 517

Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis, 580

When Are Placebo-Controlled Trials No Longer Appropriate?, 602

**TOAST**

Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 358

**TOBACCO CONTROL**

Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias, 383



**TRACKING**

- Tracking and Follow-Up of 16,915  
Adolescents: Minimizing  
Attrition Bias, 383

**TREATMENT GROUPS**

- Use of Irwin's Restricted Mean as an  
Index for Comparing Survival in  
Different Treatment  
Groups—Interpretation and  
Power Considerations, 151

**USER REVIEW**

- A User's Review of Commercial Sample  
Size Software for Design of  
Biomedical Studies Using Survival  
Data, 65

**VACCINE TRIALS**

- Can We Reduce the Dose of a Vaccine?, 43  
A Review of the Design of Vaccine

- Efficacy Trials and a Proposal for  
the Design of the VA Cooperative  
Study of Active Immunotherapy  
of HIV Infection, 397

**VALID INFERENCE**

- Secondary Endpoints Cannot Be Validly  
Analyzed if the Primary  
Endpoint Does Not Demonstrate  
Clear Statistical Significance,  
550, 557

**ZUCKER-WITTES MODIFIED RATIO  
ESTIMATE STATISTICS**

- An Application of the Zucker-Wittes  
Modified Ratio Estimate in the  
Post Coronary Artery Bypass  
Graft (CABG) Clinical Trial, 318

